Submit Manuscript

International Journal of Pharmacology

Year: 2018 | Volume: 14 | Issue: 6 | Page No.: 866-872
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend

Total views 136

Authors

Yuanyuan Liu

Haili Shen

Haili Shen

Keywords

Research Article

Salvianolic Acid B Administration Attenuate Bone Loss in Ovariectomy Induced Rat Model

Yuanyuan Liu and Haili Shen Haili Shen's LiveDNA
Background and Objective: Osteoporosis is a chronic progressive skeletal disorder characterized by low Bone Mass Density (BMD) and bone quality. This study was aimed to access the anti-osteoporotic effects of salvianolic acid B (SAB-B) against ovariectomy-induced in rat model. Materials and Methods: Forty female (n = 40) rats were randomly chosen and divided into four groups as sham-operated control (underwent bilateral laparotomy; sham group, n=10), whereas rats underwent laparotomy followed by bilateral ovariectomy (ovariectomy model group; OVX, n= 10). Whereas, OVX underwent rats were orally supplemented with either 20 or 40 mg kg–1 of SAB-B (OVX+20 or 40 mg kg–1 SAB-B group; n= 10) for 12 weeks after 4 weeks of OVX. Statistical difference between the experimental groups were analyzed by student t-test using SPSS software at p<0.05. Results: Treatment with SAB-B (20 or 40 mg kg–1), substantially increased the body weight than OVX rats. A pronounced elevation in the levels of Bone Mineral Density/Content (BMD/BMC) and body weight were observed in SAB-B treated group as compared to OVX group. Bone markers like deoxypyridinoline, alkaline phosphatase and osteocalcin as well as inflammatory markers like IL-1β, IL-6, TNF-α concentrations were significantly abolished after 12 weeks of administration with SAB-A in OVX rats. Furthermore, the bone biomechanical stability was notably improved upon supplementation with SAB-B. Conclusion: Both SAB-B 20 and 40 mg kg–1 treatment exhibit potent anti-osteoporotic activity, nevertheless SAB-B 40 showed superior anti-osteoporotic activity than SAB-B 20. Therefore, SAB-B would be recommended for treating post-menopausal osteoporosis with other standard drugs.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *